Add-on treatment with Cerebrolysin improves clinical symptoms in patients with ALS: results from a prospective, single-center, placebo-controlled, randomized, double-blind, phase II study
Firstenfeld AJ, Listorti J, Jalaff N, Loaiza Orozco CP, Navarrete Gosdenovich F, Schurr T · 2023 · J Med Life 16:1750-1755
Reported findings and study design
At one month, ALSFRS-R improved 2.3 points with add-on Cerebrolysin while declining 0.9 points with placebo (p=0.005).
Dose, route and schedule
Cerebrolysin 10 mL intravenously five days/week in month one and three days/week in months two and three; riluzole 50 mg twice daily in both groups. Historical study methods, not personal-use instructions.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ALSFRS-R change | +2.3 versus −0.9 points | Month 1 primary endpoint · p=0.005 |
| Study duration | 3 months | Benefit reported as maintained; no survival estimate in abstract |
Single-center phase II pilot, ten patients per arm; short functional findings do not establish survival benefit.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Single-center phase II pilot, ten patients per arm; short functional findings do not establish survival benefit.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Original journal report
Citation and original source
Original source: Firstenfeld AJ, Listorti J, Jalaff N, Loaiza Orozco CP, Navarrete Gosdenovich F, Schurr T. Add-on treatment with Cerebrolysin improves clinical symptoms in patients with ALS: results from a prospective, single-center, placebo-controlled, randomized, double-blind, phase II study J Med Life 16:1750-1755 2023.
Molekul research summary: https://molekul.io/research/placebo-38585517. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry